MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
sale of common stock...
$27,544K
Cash proceeds for
amendment of warrants
$67K
Exercise of warrants for
cash
$1K
Net cash provided by
financing activities
$27,612K
Net increase
(decrease) in cash
$3,829K
Canceled cashflow
$23,783K
Impairment of acquired
in-process research and...
$16,514K
Stock-based compensation
$9,910K
Accounts payable and
accrued liabilities
$1,855K
Depreciation expense
$84K
Operating lease liability
$43K
Net cash used in
operating activities
-$22,582K
Net cash used in
investing activities
-$1,042K
Impact on cash from
foreign currency...
-$159K
Canceled cashflow
$28,406K
Net loss
-$45,933K
Purchase of fixed assets
$1,042K
Research and development
tax credit...
$3,103K
Gain on settlement of
accounts payable
-$626K
Deferred liabilities
-$517K
Other assets
$516K
Prepaid expenses and
other current assets
$264K
Other tax receivable
$29K
Back
Back
Cash Flow
source: myfinsight.com
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)